Piers A Blombery

List of Publications by Year
in descending order

72	1,984	331538 21	265120 42
papers	citations	h-index	g-index

74	74	74	3112
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL. Blood, 2022, 139, 1198-1207.	0.6	34
2	Single-cell sequencing demonstrates complex resistance landscape inÂCLL and MCL treated with BTK and BCL2 inhibitors. Blood Advances, 2022, 6, 503-508.	2.5	16
3	Findings from precision oncology in the clinic: rare, novel variants are a significant contributor to scaling molecular diagnostics. BMC Medical Genomics, 2022, 15, 70.	0.7	2
4	Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review. European Journal of Haematology, 2022, 108, 469-485.	1.1	4
5	Methylâ€CpG binding domain 4, DNA glycosylase (<scp>MBD4</scp>)â€associated neoplasia syndrome associated with a homozygous missense variant in MBD4 : Expansion of an emerging phenotype. British Journal of Haematology, 2022, , .	1.2	2
6	Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm- overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement. Pathology, 2022, , .	0.3	2
7	Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative. Pathology, 2021, 53, 487-492.	0.3	0
8	Myeloid somatic mutation panel testing in myeloproliferative neoplasms. Pathology, 2021, 53, 339-348.	0.3	13
9	CAR-T cell therapy: practical guide to routine laboratory monitoring. Pathology, 2021, 53, 408-415.	0.3	10
10	T cell receptor beta locus sequencing early post-allogeneic stem cell transplant identifies patients at risk of initial and recurrent cytomegalovirus infection. Bone Marrow Transplantation, 2021, 56, 2582-2590.	1.3	2
11	Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood, 2021, 138, 1391-1405.	0.6	87
12	Cryptic molecular lesion in acute promyelocytic leukemia with negative initial FISH. Leukemia and Lymphoma, 2021, 62, 3060-3062.	0.6	1
13	T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease. Bone Marrow Transplantation, 2021, 56, 2857-2859.	1.3	7
14	Transient, flexible gene editing in zebrafish neutrophils and macrophages for determination of cell-autonomous functions. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	11
15	Response to everolimus in a patient with refractory HGBL-NOS harboring multiple genomic aberrations in PTEN. Leukemia and Lymphoma, 2021, , 1-5.	0.6	1
16	Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target. British Journal of Haematology, 2021, 195, 113-118.	1.2	8
17	Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. Blood Advances, 2021, 5, 4054-4058.	2.5	39
18	Expert Curation of Somatic FLT3 Variants By the Clingen Somatic Hematologic Cancer Taskforce (ClinGen HCT). Blood, 2021, 138, 4387-4387.	0.6	0

#	Article	IF	Citations
19	Mechanisms of intrinsic and acquired resistance to venetoclax in B-cell lymphoproliferative disease. Leukemia and Lymphoma, 2020, 61, 257-262.	0.6	15
20	Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. Blood Advances, 2020, 4, 4849-4859.	2.5	14
21	Clonal independence of <i>JAK2</i> and <i>CALR</i> or <i>MPL</i> mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing. Haematologica, 2020, 106, 313-315.	1.7	17
22	Recovery of natural killer cell cytotoxicity in a A91V perforinhomozygous patient following severe haemophagocytic lymphohistiocytosis. British Journal of Haematology, 2020, 190, 458-461.	1.2	2
23	Utility of clinical comprehensive genomic characterization for diagnostic categorization in patients presenting with hypocellular bone marrow failure syndromes. Haematologica, 2020, 106, 64-73.	1.7	14
24	Diagnostic evaluation and considerations in hypocellular bone marrow failureâ€"A focus on genomics. International Journal of Laboratory Hematology, 2020, 42, 82-89.	0.7	4
25	A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability. British Journal of Haematology, 2020, 190, e297-e301.	1.2	14
26	High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot. , 2020, 8, e000792.		45
27	Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of Bâ€acute lymphoblastic leukaemia. British Journal of Haematology, 2020, 191, 123-126.	1.2	5
28	Severe chemotherapy toxicity in a 10-year-old with T-acute lymphoblastic lymphoma harboring biallelic FANCM variants. Leukemia and Lymphoma, 2020, 61, 1257-1259.	0.6	2
29	Detection of an IGH-BRAF fusion in a patient with BRAF Val600Glu negative hairy cell leukemia. Leukemia and Lymphoma, 2020, 61, 2024-2026.	0.6	6
30	Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. Blood, 2020, 135, 773-777.	0.6	115
31	Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. Blood Advances, 2020, 4, 165-173.	2.5	34
32	Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study. Blood, 2020, 136, 43-44.	0.6	9
33	Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Blood, 2020, 136, 7-8.	0.6	13
34	BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Blood, 2020, 135, 2266-2270.	0.6	67
35	A Phase II, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of the Combination of Tisagenlecleucel and Ibrutinib in Mantle Cell Lymphoma (TARMAC). Blood, 2020, 136, 34-35.	0.6	4
36	Longitudinal Genomic Characterization Using Cell-Free DNA in Patients with Idiopathic Aplastic Anemia. Blood, 2020, 136, 5-6.	0.6	0

#	Article	IF	Citations
37	High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia. Blood, 2020, 136, 15-16.	0.6	2
38	Mutational and Copy Number Profiling of Circulating Tumor DNA in Acute Myeloid Leukemia Using Targeted Next Generation Sequencing. Blood, 2020, 136, 39-40.	0.6	2
39	Expert Curation of Somatic Variants in Hematological Malignancies By the Clingen Somatic Hematological Cancer Taskforce (ClinGen HCT). Blood, 2020, 136, 23-23.	0.6	0
40	Circulating tumor DNA for disease monitoring in the era of CAR T-cell therapy. Leukemia and Lymphoma, 2019, 60, 279-280.	0.6	0
41	Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma. British Journal of Haematology, 2019, 186, e188-e191.	1.2	37
42	Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nature Communications, 2019, 10, 2385.	5.8	139
43	First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. Cancer Discovery, 2019, 9, 1036-1049.	7.7	129
44	CNspector: a web-based tool for visualisation and clinical diagnosis of copy number variation from next generation sequencing. Scientific Reports, 2019, 9, 6426.	1.6	17
45	Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2ÂMutation or Concurrent MDS. HemaSphere, 2019, 3, e187.	1.2	14
46	Molecular Drivers of Breast Implantâ€“Associated Anaplastic Large Cell Lymphoma. Plastic and Reconstructive Surgery, 2019, 143, 59S-64S.	0.7	28
47	What does good FISHing look like in MDS?. Leukemia and Lymphoma, 2019, 60, 571-572.	0.6	0
48	Dynamic molecular monitoring reveals that SWIâ€“SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nature Medicine, 2019, 25, 119-129.	15.2	147
49	Revisiting acquired aplastic anaemia: current concepts in diagnosis and management. Internal Medicine Journal, 2019, 49, 152-159.	0.5	15
50	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Discovery, 2019, 9, 342-353.	7.7	306
51	BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib. Blood, 2019, 134, 170-170.	0.6	33
52	Characterization of the "Immune Evasion" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy. Blood, 2019, 134, 4290-4290.	0.6	0
53	Sensitive NPM1 Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory. Archives of Pathology and Laboratory Medicine, 2018, 142, 606-612.	1.2	8
54	Incidental detection of germline variants of potential clinical significance by massively parallel sequencing in haematological malignancies. Journal of Clinical Pathology, 2018, 71, 84-87.	1.0	18

#	Article	IF	Citations
55	Detection of clinically relevant early genomic lesions in Bâ€cell malignancies from circulating tumour <scp>DNA</scp> using a single hybridisationâ€based next generation sequencing assay. British Journal of Haematology, 2018, 183, 146-149.	1.2	8
56	Adaptive reprogramming of NK cells in X-linked lymphoproliferative syndrome. Blood, 2018, 131, 699-702.	0.6	5
57	The price of success-health economics of personalized diffuse large B-cell lymphoma treatment. Leukemia and Lymphoma, 2018, 59, 1517-1519.	0.6	1
58	Comprehensive genomic characterization dissects the complex biology of a case of synchronous Burkitt lymphoma and myeloid malignancy with shared hematopoietic ancestry. Leukemia and Lymphoma, 2018, 59, 992-995.	0.6	2
59	Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy. Blood Advances, 2018, 2, 335-346.	2.5	47
60	Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing. Journal of Clinical Pathology, 2018, 71, 895-899.	1.0	28
61	Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma. Oncotarget, 2018, 9, 36126-36136.	0.8	62
62	Providing Diagnoses in Bone Marrow Failure Syndromes through Multimodal Comprehensive Genomic Evaluation and Multidisciplinary Care: The Melbourne Genomics Health Alliance Bone Marrow Failure Flagship. Blood, 2018, 132, 3867-3867.	0.6	0
63	Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory. Annals of Hematology, 2017, 96, 725-732.	0.8	17
64	Primary Breast Lymphomaâ€"Population-Level Insights into an Infrequent but Increasingly Recognized Subtype of Lymphoma. Journal of the National Cancer Institute, 2017, 109, .	3.0	5
65	Canary: an atomic pipeline for clinical amplicon assays. BMC Bioinformatics, 2017, 18, 555.	1.2	4
66	Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma. Haematologica, 2016, 101, e387-e390.	1.7	124
67	Copper deficiency mimicking myelodysplastic syndrome. Leukemia and Lymphoma, 2016, 57, 1223-1226.	0.6	1
68	The molecular pathogenesis of Bâ€cell nonâ€Hodgkin lymphoma. European Journal of Haematology, 2015, 95, 280-293.	1.1	22
69	Molecular lesions in B-cell lymphoproliferative disorders: recent contributions from studies utilizing high-throughput sequencing techniques. Leukemia and Lymphoma, 2014, 55, 19-30.	0.6	5
70	Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders. Haematologica, 2012, 97, 780-783.	1.7	63
71	Erdheim-Chester Disease Harboring the BRAF V600E Mutation. Journal of Clinical Oncology, 2012, 30, e331-e332.	0.8	46
72	Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications. Annals of Hematology, 2011, 90, 1167-1172.	0.8	27